Upstream Bio, Inc.

Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders. Its lead product candidate is verekitug, a monoclonal antibody designed to target the thymic stromal lymphopoietin (TSLP) pathway, which plays a key role in inflammation. Verekitug is currently in Phase 2 clinical trials for severe asthma and chronic rhinosinusitis with nasal polyps, and also in Phase 2 for chronic obstructive pulmonary disease (COPD). Additionally, it is being evaluated in a Phase 1 trial for COPD. The company aims to address significant unmet medical needs in respiratory conditions where current therapies are limited.

Upstream Bio, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol UPB. Its shares are traded in US Dollars (USD), reflecting its primary listing in the United States. The NasdaqGS is a major US stock exchange known for hosting many biotechnology and technology companies, providing liquidity and visibility for investors.

Upstream Bio operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative therapies using biological processes. Its work is centered on inflammatory diseases, with a particular emphasis on severe respiratory disorders such as asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease (COPD). The company's clinical-stage pipeline reflects its commitment to advancing treatments in this specialized area of medicine.

Upstream Bio, Inc. is headquartered in Waltham, Massachusetts, United States. The company was incorporated in 2021, making it a relatively young player in the biotechnology space. Its location in Massachusetts places it within a prominent biotech hub, providing access to talent, research institutions, and potential partnerships. The company's focus on developing treatments for inflammatory respiratory diseases aligns with the region's strong life sciences ecosystem.